AbRegen uses UniSA’s patented technologies to develop first-in class antibody-based therapeutics targeting the protein Flightless-I to treat dermatological and immuno-inflammatory conditions. This approach is the only current known technology developed against the Flightless I target. Is active in multiple immuno-inflammatory conditions such as Irritable Bowel Disease and the systemic Ab treatment has a dual effect both internally (gut) and on the skin.
abregen.com.au
Some of these cookies are essential for the website to function correctly, while others may collect your personal information. In some cases, the personal information collected by our cookies may be shared with third party service providers.
For details about the categories of cookies that we use, and to set your cookie preferences, please select ‘More information’ before you continue. For an overview see our Privacy Statement, or review our Privacy Policy in full.